Clavipectoral Block Versus Interscalene Block for Postoperative Analgesia in Midshaft Clavicular Surgery
Launched by AIN SHAMS UNIVERSITY · Apr 4, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain relief after surgery for a midshaft clavicle fracture, which is a break in the collarbone. The two methods being compared are called the Interscalene Block and the Clavipectoral Block. Both techniques aim to help patients feel less pain following their surgery, but the researchers want to see which one works better.
To join the study, participants need to be between 21 and 60 years old and in good health, classified as ASA class I or II, which means they are at low risk from anesthesia. However, some people may not be eligible, including those with certain health issues, pregnant women, or those with a history of drug allergies. If you decide to take part, you can expect to receive one of the two pain relief techniques during your surgery, and researchers will monitor your recovery to see how well each method helps with pain management. This study is currently recruiting participants, and your involvement could help improve pain relief options for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged from 21 to 60 years.
- • American Society of Anesthesiologists (ASA) class I and II status.
- • Of both sexes.
- • Patients undergoing elective midshaft clavicle fracture open reduction and internal fixation surgery.
- Exclusion Criteria:
- • Patient refusal.
- • American Society of Anesthesiologists (ASA) class llI and IV status.
- • Patients with bleeding disorders.
- • A history of relevant drug allergy to any of the used drugs.
- • Alcohol or drug abuse and opioid dependence.
- • Pregnant female patients.
- • Patients with BMI above 30 kg/m2.
- • Patients with infection at site of the fracture or the block procedure.
- • Patients with reduced pulmonary functions due to chronic obstructive pulmonary disease (COPD), uncontrolled asthma, pneumothorax or pleural effusion.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Abbasia, Egypt
Patients applied
Trial Officials
Moustafa K Reyad, Professor
Study Director
Ain Shams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported